PUBLISHER: TechNavio | PRODUCT CODE: 2078141
PUBLISHER: TechNavio | PRODUCT CODE: 2078141
The global human microbiome therapeutics market is forecasted to grow by USD 943069.2 thousand during 2025-2030, accelerating at a CAGR of 20.5% during the forecast period. The report on the global human microbiome therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising incidence of chronic gastrointestinal and metabolic diseases, technological advancements in metagenomic sequencing and ai, accelerated regulatory pathways and increasing capital inflows.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 18.2% |
| CAGR | 20.5% |
| Incremental Value | $943069.2 thousand |
Technavio's global human microbiome therapeutics market is segmented as below:
By Product
By Application
By Route Of Administration
Geography
This study identifies the transition toward rationally designed and engineered synthetic consortia as one of the prime reasons driving the global human microbiome therapeutics market growth during the next few years. Also, integration of microbiome-based therapies as immuno-oncology adjuvants and expansion of clinical focus beyond gastrointestinal targets to gut-brain axis will lead to sizable demand in the market.
The report on the global human microbiome therapeutics market covers the following areas:
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global human microbiome therapeutics market vendors that include BioGaia Group, BiomeBank, Danone SA, Ferring BV, International Flavors Inc., Johnson and Johnson, Lallemand Inc., Morinaga Milk Industry, Nestle Health Science S.A., Novonesis Group, OptiBiotix Health Plc, Pendulum Therapeutics Inc., Probi AB, ResBiotic, Seed Health, Takeda Pharmaceutical Ltd., Vedanta Biosciences Inc., Yakult Honsha Co. Ltd.. Also, the global human microbiome therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.